



## Xenotransplantation: Targeting Acute Vascular Rejection and Endothelial Activation

Guest Editor:

**Dr. Konrad Fischer**

School of Life Sciences  
Weihenstephan, Technische  
Universität München, 85354  
Freising, Germany

Deadline for manuscript  
submissions:

**closed (31 August 2024)**

### Message from the Guest Editor

Dear Colleagues,

Acute vascular rejection (AVR) still presents a major hurdle to long-term xenograft acceptance. Although several transgene combinations and knockouts have been described, xenografts are still undergoing AVR. New insights into innate and adaptive immune responses as well as detailed characterizations of signaling pathways are necessary to further optimize the pigs and protect the xenografts. In this Special Issue, we focus on the role of the endothelium during AVR, including the endothelial glycocalyx and underlying signaling pathways, and investigate new means of overcoming blood coagulation mechanisms and thrombotic microangiopathy (TMA).

Dr. Konrad Fischer  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI